0.71
+0.0628(+9.75%)
Currency In USD
Address
200 Clarendon Street
Boston, MA 02116
United States of America
Phone
650 503 9095
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
152
First IPO Date
January 08, 2021
| Name | Title | Pay | Year Born |
| Mr. Chen Schor BA, CPA, M.B.A. | Chief Executive Officer, President & Director | 888,012 | 1972 |
| Dr. Aya Jakobovits Ph.D. | Founder & Independent Director | 45,000 | 1955 |
| Dr. Donald Healey Ph.D. | Chief Technology Officer | 606,337 | 1962 |
| Mr. Brian Nicholas Harvey | Chief Financial Officer | 611,141 | 1961 |
| Dr. Blake Aftab Ph.D. | Senior Vice President & Chief Scientific Officer | 693,817 | 1981 |
| Dr. Julie Maltzman M.D. | Chief Medical Officer | 0 | N/A |
| Ms. Amy Locke | Chief Human Resource Officer | 0 | N/A |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.